Donella S Young, MD | |
100 3rd St, Suite 1, Davenport, WA 99122-9730 | |
(509) 725-7501 | |
(509) 725-7504 |
Full Name | Donella S Young |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 100 3rd St, Davenport, Washington |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073554119 | NPI | - | NPPES |
8154353 | Medicaid | WA | |
CJ6525 | Other | WA | MEDICARE RAILROAD |
080187185 | Other | WA | MEDICARE RAILROAD |
7101132 | Medicaid | WA | |
7117450 | Medicaid | WA | |
154736 | Other | WA | DEPT. OF L & I |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | MD00026777 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Donella S Young, MD 100 3rd St, Suite 1, Davenport, WA 99122-9730 Ph: (509) 725-7501 | Donella S Young, MD 100 3rd St, Suite 1, Davenport, WA 99122-9730 Ph: (509) 725-7501 |
News Archive
Food allergies are more common among people with asthma and may contribute to asthma attacks, according to one of the most comprehensive surveys of food allergies ever undertaken.
In what may be a major leap forward in the quest for new treatments of the most common form of cardiovascular disease, scientists at Johns Hopkins report they have found a way to halt and reverse the progression of atherosclerosis in rodents by loading microscopic nanoparticles with a chemical that restores the animals' ability to properly handle cholesterol.
MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.
Selvita sp. z o.o., from Krakow, Poland and Orion Corporation from Espoo, Finland (ORNBV) today announced that they have entered into a global collaboration to jointly develop and commercialize SEL103, Selvita's proprietary program for the treatment of Alzheimer's disease and other cognitive disorders. Selvita will be responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization.
› Verified 7 days ago
Dr. Frederick Joseph Reed, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 3rd Street, Suite 1, Davenport, WA 99122 Phone: 509-725-7501 Fax: 509-725-7504 |